RECARBRIO
Total Payments
$3.5M
Transactions
1,408
Doctors
484
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $316,363 | 56 | 24 |
| 2023 | $673,170 | 220 | 128 |
| 2022 | $1.0M | 199 | 93 |
| 2021 | $629,526 | 423 | 268 |
| 2020 | $245,840 | 148 | 18 |
| 2019 | $601,615 | 362 | 9 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.2M | 489 | 92.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $140,520 | 59 | 4.0% |
| Consulting Fee | $49,608 | 25 | 1.4% |
| Travel and Lodging | $40,504 | 131 | 1.2% |
| Food and Beverage | $28,632 | 701 | 0.8% |
| Education | $59.43 | 3 | 0.0% |
Payments by Type
Research
$3.2M
489 transactions
General
$259,324
919 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Imipenem-Relebactam Plus Vancomycin, Linezolid Versus Standard Of Care Plus Vancomycin, Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer | Merck Sharp & Dohme LLC | $869,947 | 0 |
| A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection | Merck Sharp & Dohme Corporation | $374,087 | 0 |
| A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection | Merck Sharp & Dohme LLC | $363,663 | 0 |
| An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Imipenem-Relebactam Plus Vancomycin, Linezolid Versus Standard Of Care Plus Vancomycin, Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer | Merck Sharp & Dohme Corporation | $337,822 | 0 |
| US KPC Burden & Post-C,A | Merck Sharp & Dohme Corporation | $193,116 | 0 |
| Structural comparison of the Klebsiella pneumoniae carbapenemase, KPC-2 and its D179 variant interactions with imipenem, relebactam, and ceftazidime Can we explain the mechanism of resistance | Merck Sharp & Dohme LLC | $175,753 | 0 |
| A Phase 1b, Open label, Single dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Children from Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections | Merck Sharp & Dohme Corporation | $142,845 | 0 |
| A Multicenter, Open-label Study to Determine the Pharmacokinetics, Safety, and Outcomes of Imipenem,Cilastatin,Relebactam during Treatment of Acute Pulmonary Exacerbations in Adolescent and Adult Patients with Cystic Fibrosis | Merck Sharp & Dohme LLC | $130,389 | 0 |
| US KPC Burden & Post-C,A U Pittsburgh | Merck Sharp & Dohme Corporation | $92,690 | 0 |
| Ex Vivo Sequestration and Pharmacokinetics of Imipenem,Cilastatin,Relebactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation ECMO | Merck Sharp & Dohme LLC | $83,712 | 0 |
| Leveraging the high potency of imipenem,relebactam against carbapenem-resistant pathogens as a potential novel streamlined treatment option for patients co-infected with multiple carbapenem-resistant organisms to improve outcome. | Merck Sharp & Dohme LLC | $82,453 | 0 |
| Impact of Obesity on the Pharmacokinetics and Pharmacodynamics of Imipenem-Relebactam in ICU Patients | Merck Sharp & Dohme LLC | $77,309 | 0 |
| Ex Vivo Sequestration and Pharmacokinetics of Imipenem,Cilastatin,Relebactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation ECMO | Merck Sharp & Dohme Corporation | $59,349 | 0 |
| STUDY NAMEA novel combination of beta-lactamase inhibitor relebactam in combination with imipenem to combat MDR infections in high-risk patients in vitro mechanisms and epidemiology | Merck Sharp & Dohme Corporation | $49,976 | 0 |
| A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial toStudy the Safety, Tolerability, and Efficacy of Imipenem,Cilastatin,Relebactam MK-7655AVersus Piperacillin,Tazobactam in Subjects with Hospital-Acquired Bacterial Pneumonia orVentilator-Associated Bacterial Pneumonia | Merck Sharp & Dohme Corporation | $46,369 | 0 |
| Systematic Literature Review of C-NS infection burden and colistin,polymixin B-Tufts Medical Center | Merck Sharp & Dohme Corporation | $41,180 | 0 |
| In vitro and in vivo activity of imipenem-relabactam alone and in combination against CF isolates of Mycobacterium abscessus. | Merck Sharp & Dohme LLC | $27,775 | 0 |
| An observation study comparing prospective use of Imipenem,Cilastatin,Relebactam IMI,REL to retrospective data using Meropenem,Vabobactam MVBand Ceftazidime,Avibactam CZA in treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae infections at a tertiary care hospital | Merck Sharp & Dohme LLC | $27,413 | 0 |
| STUDY NAME:Relebactam Clearance During Continuous Renal replacement Therapy (CRRT): An Ex vivo investigation | Merck Sharp & Dohme Corporation | $19,974 | 0 |
| STUDY NAME:Real-world experience of Imipenem-Relebactam for treating Pseudomonas aeruginosa infection in clinics | Merck Sharp & Dohme Corporation | $15,675 | 0 |
Top Doctors Receiving Payments for RECARBRIO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Iowa City, IA | $3.2M | 489 |
| , M.D | Critical Care Medicine | Brooklyn, NY | $43,308 | 59 |
| , MD | Pediatric Infectious Diseases | Durham, NC | $18,500 | 10 |
| , M.D | Infectious Disease | Charlotte, NC | $15,437 | 19 |
| , M.D | Pulmonary Disease | Abington, PA | $14,697 | 14 |
| , D.O | Infectious Disease | Turlock, CA | $12,550 | 14 |
| , MD | Pediatric Infectious Diseases | Dallas, TX | $11,558 | 13 |
| , MD | Pulmonary Disease | Washington, DC | $8,967 | 9 |
| , M.D | Surgery | Pittsburgh, PA | $8,925 | 7 |
| , M.D | Internal Medicine | Boston, MA | $8,424 | 6 |
| , MD | Infectious Disease | Philadelphia, PA | $7,184 | 5 |
| , MD | Infectious Disease | Memphis, TN | $6,833 | 7 |
| , M.D | Infectious Disease | Sylmar, CA | $6,690 | 3 |
| , MD | Internal Medicine | Sacramento, CA | $6,086 | 4 |
| , MD | Emergency Medicine | Pittsburgh, PA | $5,665 | 3 |
| , MD | Infectious Disease | Pasadena, CA | $4,696 | 6 |
| , MD | Infectious Disease | Lexington, KY | $4,574 | 4 |
| , MD, MPH | Infectious Disease | Maywood, IL | $4,451 | 6 |
| , MD, MPH | Infectious Disease | Roseville, CA | $4,391 | 4 |
| , DO | Infectious Disease | Altamonte Springs, FL | $4,130 | 2 |
| , M.D | Infectious Disease | Santa Monica, CA | $4,015 | 4 |
| , MD | Infectious Disease | Philadelphia, PA | $3,524 | 3 |
| , MD | Infectious Disease | Fort Worth, TX | $2,991 | 4 |
| , M.D | Infectious Disease | Murrieta, CA | $2,857 | 9 |
| , M.D | Pediatric Emergency Medicine | Austin, TX | $2,813 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.5M
- Total Doctors 484
- Transactions 1,408
About RECARBRIO
RECARBRIO is a drug associated with $3.5M in payments to 484 healthcare providers, recorded across 1,408 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2024. In 2024, $316,363 was paid across 56 transactions to 24 doctors.
The most common payment nature for RECARBRIO is "Unspecified" ($3.2M, 92.6% of total).
RECARBRIO is associated with 20 research studies, including "An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Imipenem-Relebactam Plus Vancomycin, Linezolid Versus Standard Of Care Plus Vancomycin, Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer" ($869,947).